Boundless Bio to Participate in the Leerink Global Healthcare Conference
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology research for treating oncogene amplified cancers, has announced its participation in the upcoming Leerink Global Healthcare Conference.
The company's President and CEO, Zachary Hornby, will engage in a fireside chat session scheduled for March 12, 2025, at 11:20 a.m. ET in Miami, FL. Investors and interested parties can access both live and archived webcasts of the presentation through the company's website under the Events & Presentations section in the Investors area.
Boundless Bio (Nasdaq: BOLD), un'azienda oncologica in fase clinica focalizzata sulla ricerca della biologia del DNA estrachromosomico (ecDNA) per il trattamento dei tumori amplificati da oncogeni, ha annunciato la sua partecipazione alla prossima Leerink Global Healthcare Conference.
Il presidente e CEO dell'azienda, Zachary Hornby, parteciperà a una sessione di chat informale programmata per il 12 marzo 2025, alle 11:20 a.m. ET a Miami, FL. Gli investitori e le parti interessate possono accedere sia alle trasmissioni in diretta che a quelle archiviate della presentazione attraverso il sito web dell'azienda nella sezione Eventi e Presentazioni nell'area Investitori.
Boundless Bio (Nasdaq: BOLD), una empresa de oncología en etapa clínica centrada en la investigación de la biología del ADN extracromosómico (ecDNA) para el tratamiento de cánceres amplificados por oncogenes, ha anunciado su participación en la próxima Leerink Global Healthcare Conference.
El presidente y CEO de la empresa, Zachary Hornby, participará en una sesión de charla informal programada para el 12 de marzo de 2025, a las 11:20 a.m. ET en Miami, FL. Los inversores y partes interesadas pueden acceder tanto a las transmisiones en vivo como a las archivadas de la presentación a través del sitio web de la empresa en la sección de Eventos y Presentaciones en el área de Inversores.
Boundless Bio (Nasdaq: BOLD)는 온코겐 증폭 암 치료를 위한 엑스트라 크로모좀 DNA (ecDNA) 생물학 연구에 중점을 둔 임상 단계의 종양학 회사로, 다가오는 Leerink Global Healthcare Conference에 참여한다고 발표했습니다.
회사의 회장 겸 CEO인 Zachary Hornby는 2025년 3월 12일 오전 11시 20분 ET에 플로리다주 마이애미에서 예정된 화상 대화 세션에 참여할 예정입니다. 투자자 및 관심 있는 당사자는 회사 웹사이트의 투자자 섹션에 있는 이벤트 및 발표 섹션을 통해 발표의 실시간 및 아카이브 웹캐스트에 접근할 수 있습니다.
Boundless Bio (Nasdaq: BOLD), une entreprise d'oncologie en phase clinique axée sur la recherche sur la biologie de l'ADN extracromosomique (ecDNA) pour le traitement des cancers amplifiés par des oncogènes, a annoncé sa participation à la prochaine Leerink Global Healthcare Conference.
Le président et PDG de l'entreprise, Zachary Hornby, participera à une session de discussion informelle prévue pour le 12 mars 2025, à 11h20 ET à Miami, FL. Les investisseurs et les parties intéressées peuvent accéder aux webcasts en direct et archivés de la présentation via le site Web de l'entreprise dans la section Événements et Présentations de la zone Investisseurs.
Boundless Bio (Nasdaq: BOLD), ein klinisch tätiges Onkologieunternehmen, das sich auf die Forschung zur Biologie von extrachromosomalem DNA (ecDNA) zur Behandlung von durch Onkogene amplifizierten Krebserkrankungen konzentriert, hat seine Teilnahme an der bevorstehenden Leerink Global Healthcare Conference bekannt gegeben.
Der Präsident und CEO des Unternehmens, Zachary Hornby, wird an einer informellen Gesprächsrunde teilnehmen, die für den 12. März 2025 um 11:20 Uhr ET in Miami, FL, geplant ist. Investoren und interessierte Parteien können sowohl auf die Live- als auch auf die aufgezeichneten Webcasts der Präsentation über die Website des Unternehmens im Bereich Veranstaltungen & Präsentationen im Investorenbereich zugreifen.
- None.
- None.
SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Leerink’s Global Healthcare Conference.
A fireside chat session is scheduled for Wednesday, March 12, 2025, in Miami, FL, at 11:20 a.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website and can be accessed via this link: https://wsw.com/webcast/leerink38/bold/2199477.
About Boundless Bio
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14 to
Contacts:
Ben Flaum, Boundless Bio
bflaum@boundlessbio.com
Investors
THRUST Strategic Communications
Renee Leck
renee@thrustsc.com
FAQ
When is Boundless Bio (BOLD) presenting at the Leerink Global Healthcare Conference 2025?
How can investors watch Boundless Bio's (BOLD) Leerink Conference presentation?
What type of cancer treatments is Boundless Bio (BOLD) developing?
What is the current development stage of Boundless Bio (BOLD)?
